A long-acting, lab-made form of amylin, a hormone that helps you feel full.
Most studied for
Large trials in people130 study results, 75 from people
Peptides / Weight and metabolic
Fixed combination of 2 peptides
CagriSema
Not approvedBanned in sport
CagriSema is a Novo Nordisk product that combines 2 peptides, cagrilintide and semaglutide. Large trials in people tested it for weight loss and for type 2 diabetes. It is not approved yet. Novo Nordisk asked the FDA to approve it in December 2025.
What is in CagriSema2 peptides
CagriSema is one fixed product. In its trials, people got both peptides together.
Evidence level: Large trials in peoplePepBank has 150 results from studies of CagriSema. 137 come from studies in people, including randomized trials.
What is in CagriSema
The 2 peptides in CagriSema
Each peptide has its own guide with all of its studies.
A GLP-1 drug, approved as Ozempic and Wegovy for diabetes and weight loss.
Most studied for
Large trials in people4,624 study results, 4,515 from people
Overview
Key points
- CagriSema combines cagrilintide and semaglutide in one product.
- PepBank has 150 results from 27 studies of CagriSema. 137 come from studies in people.
- Trials in people tested CagriSema for weight loss and for type 2 diabetes.
- CagriSema is not approved. Novo Nordisk asked the FDA to approve it in December 2025, and PepBank found no decision as of October 30, 2026.
- Semaglutide is approved on its own. Cagrilintide is not.
- CagriSema is banned in sport, because WADA bans unapproved substances such as cagrilintide.
CagriSema at a glance
| What it is | A fixed combination of 2 peptides |
|---|---|
| What is in it | Cagrilintide, Semaglutide |
| Studies of CagriSema | 27 published |
| Clinical trials | 28 registered |
| Research on its peptides | 4,754 study results. 4,590 come from people. |
| Approved in the US? | No |
| Allowed in sport? | No. WADA bans cagrilintide. Semaglutide alone is not banned. |
| Recipe | One fixed product from Novo Nordisk. |
The evidence
Studies of CagriSema
27 published studies reported results for CagriSema. The list starts with the largest trials in people.
27
published studies of CagriSema
- PeopleCagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.7 resultsRandomized trial · 1,206 people · The New England journal of medicine · 2025
- PeopleEfficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.4 resultsRandomized trial · 331 people · The lancet. Diabetes & endocrinology · 2026
- PeopleCagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.7 resultsRandomized trial · 274 people · Lancet (London, England) · 2026
- PeopleCagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.5 resultsRandomized trial · 167 people · Hypertension (Dallas, Tex. : 1979) · 2026
- PeopleEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.7 resultsRandomized trial · 125 people · The lancet. Diabetes & endocrinology · 2026
- PeopleSafety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.3 resultsRandomized trial · 95 people · Lancet (London, England) · 2021
- PeopleEfficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.11 resultsRandomized trial · 31 people · Lancet (London, England) · 2023
- PeopleEfficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.1 resultRandomized trial · The lancet. Gastroenterology & hepatology · 2026
Clinical trials of CagriSema
28 registered trials test cagrilintide and semaglutide together.
- 3REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · Active, not recruiting · 7,101 people
- 3A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · Active, not recruiting · 3,400 people
- 3
- 3
- 3A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · Completed · 1,200 people
- 3
- 3
- 3A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 · Completed · 809 people
How much research each peptide has
Semaglutide has far more research than cagrilintide. Both bars use the same scale, so you can compare them.
What the 2 peptides were studied for
Both peptides were studied most for weight and for blood sugar. Almost all of the semaglutide research comes from people.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Weight and appetite1,112 from people | 56 | 1,105 |
| Blood sugar676 from people | 12 | 672 |
| Heart and blood vessels458 from people | 4 | 464 |
| Liver174 from people | – | 179 |
| Daily life and fitness150 from people | – | 150 |
| Kidneys and bladder135 from people | – | 136 |
| Cholesterol and blood fats119 from people | 2 | 118 |
Each number counts study results. A bigger circle means more results.
Status and safety
Is CagriSema approved?
No. CagriSema is not approved yet. Semaglutide is approved on its own, but cagrilintide is not.
| US FDA | Sport (WADA) | HHS draft policy | |
|---|---|---|---|
| Cagrilintide | Not approved | BannedS0 | Not covered |
| Semaglutide | Approved | Not banned in sport | Not covered |
| CagriSema itself | Not approved | BannedContains banned peptides | Not covered. The policy covers one peptide per product. |
The FDA says that cagrilintide cannot be used in compounding under federal law. The HHS draft compounding policy from October 2026 does not cover CagriSema.
Is CagriSema safe?
Trials in people reported the side effects of CagriSema.
The most common side effects were in the stomach and gut. Meta-analyses found more nausea and vomiting with CagriSema than with semaglutide alone.
Each peptide guide lists its own safety results.
Questions and more
Common questions
What is CagriSema?
CagriSema is a Novo Nordisk product that combines 2 peptides, cagrilintide and semaglutide. It is not approved yet.
Is CagriSema approved?
Not yet. Novo Nordisk asked the FDA to approve it in December 2025. PepBank found no FDA or EMA decision as of October 30, 2026.
What did trials of CagriSema test?
Trials in people tested CagriSema for weight loss in adults with overweight or obesity, and for blood sugar in adults with type 2 diabetes.
Is CagriSema banned in sport?
Yes. WADA bans unapproved substances, and cagrilintide is not approved. Semaglutide alone is not banned.
Can a pharmacy make CagriSema?
No. The FDA says that cagrilintide cannot be used in compounding under federal law. The HHS draft policy from October 2026 does not cover it.
Ask a question about CagriSema
The answer links to every study it uses.
Sources
- Company: Novo Nordisk, FDA application announcement, December 18, 2025
- Registry: ClinicalTrials.gov, CagriSema phase 3 trial NCT05567796
- Regulator: WADA 2026 Prohibited List, effective January 1, 2026
- Regulator: WADA 2026 Monitoring Program, item 6
- Company: Novo Nordisk regulatory pathway and milestones, June 7, 2026
- Regulator: FDA statement on compounding with cagrilintide
- Regulator: EMA paediatric waiver decision, August 4, 2023
- Regulator: EMA paediatric plan modification, May 15, 2025, published July 14, 2026
- Registry: ClinicalTrials.gov, CagriSema phase 3 trial NCT05394519
- Registry: ClinicalTrials.gov, CagriSema phase 3 trial NCT05669755
- PepBank: Pages for cagrilintide and semaglutide, as of November 5, 2026. Each page lists its own sources.
AI wrote this page from the sources above. AI can make mistakes, so check important facts against the source.
PepBank does not sell peptides, and Curo is the only shop it links to.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Ask your AI about CagriSema
